Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody–Drug Conjugate as a Therapeutic for Non–Small Cell Lung and Ovarian Cancers [PDF]
Clinical Cancer Research, 2015 Abstract Purpose: Antibody–drug conjugates (ADC) selectively deliver a cytotoxic drug to cells expressing an accessible antigenic target. Here, we have appended monomethyl auristatin E (MMAE) to an antibody recognizing the SLC34A2 gene product NaPi2b, the type II sodium–phosphate cotransporter, which is highly expressed on tumor surfaces
Bonnee Rubinfeld +10 more
openaire +3 more sources
Cancer Medicine, Volume 13, Issue 21, November 2024.ABSTRACT Background Antibody‐drug conjugates (ADC) have emerged as a highly promising systemic option in the treatment of recurrent ovarian cancer. The present study aimed to evaluate the treatment efficacy of folate receptor α (FRα)‐targeting ADCs, associated treatment‐related adverse events (TRAEs), and their impact on treatment safety.
Eun Taeg Kim +6 more
wiley +1 more source
High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients
Tumor Biology, 2017 Dysregulation of SLC34A2 (NaPi2b) in tumors has attracted wide attention, but its expression and function in non–small cell lung cancer remains unclear.
Zhaoxuan Zhang +6 more
doaj +1 more source
Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies
MedComm, Volume 5, Issue 8, August 2024.The antibodies of ADCs bind to antigens on the cell surface, forming ADC–antigen complexes. These complexes are subsequently internalized into lysosomes via receptor‐mediated endocytosis. Once inside the lysosomes, the ADCs can be degraded by enzymes or the acidic environment, releasing cytotoxic payloads that can disrupt DNA or inhibit microtubule ...
Jun He +4 more
wiley +1 more source
Development of antibody‐drug conjugates in cancer: Overview and prospects
Cancer Communications, Volume 44, Issue 1, Page 3-22, January 2024.Abstract In recent years, remarkable breakthroughs have been reported on antibody‐drug conjugates (ADCs), with 15 ADCs successfully entering the market over the past decade. This substantial development has positioned ADCs as one of the fastest‐growing domains in the realm of anticancer drugs, demonstrating their efficacy in treating a wide array of ...
Dan‐Yun Ruan +3 more
wiley +1 more source
Micro-patterned culture of iPSC-derived alveolar and airway cells distinguishes SARS-CoV-2 variants. [PDF]
iPS細胞から作った肺胞や気道の細胞によりSARS-CoV-2変異株の病原性を比較評価する. 京都大学プレスリリース. 2024-03-29.Micro-patterning a new system to induce alveolar and airway epithelial cells. 京都大学プレスリリース.
Gotoh, Shimpei +7 more
core +1 more source
2022-RA-439-ESGO Up-next (ENGOT-Ov71-NSGO-CTU/GOG-3049): a study of upitifamab rilsodotin (UpRi), a napi2b-directed antibody drug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer [PDF]
, 2022 Mansoor Raza Mirza +7 more
openalex +1 more source
Clinical Evaluation of Niacin in Hemodialysis Patients with Hyperphosphatemia as Adjuvant to Calcium Carbonate [PDF]
, 2020 Background: The complications of End Stage Renal Disease ESRD attributed to high morbidity and mortality such as hyperphosphatemia and vascular disease.
Mohammed Mahmood Mohammed +2 more
core +2 more sources
EP014/#408 Evaluation of NAPI2B expression in a well annotated longitudinal tissue series of ovarian serous carcinomas [PDF]
, 2022 Ronny Drapkin +4 more
openalex +1 more source
Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer [PDF]
, 2019 David E. Gerber +26 more
+4 more sources